These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

342 related articles for article (PubMed ID: 24595035)

  • 1. Early experiences implementing pre-exposure prophylaxis (PrEP) for HIV prevention in San Francisco.
    Liu A; Cohen S; Follansbee S; Cohan D; Weber S; Sachdev D; Buchbinder S
    PLoS Med; 2014 Mar; 11(3):e1001613. PubMed ID: 24595035
    [TBL] [Abstract][Full Text] [Related]  

  • 2. When is good good enough for HIV-1 prophylaxis?
    Buchbinder S
    Lancet Infect Dis; 2014 Nov; 14(11):1024-1025. PubMed ID: 25300861
    [No Abstract]   [Full Text] [Related]  

  • 3. Concentrations of tenofovir and emtricitabine in saliva: implications for preexposure prophylaxis of oral HIV acquisition.
    de Lastours V; Fonsart J; Burlacu R; Gourmel B; Molina JM
    Antimicrob Agents Chemother; 2011 Oct; 55(10):4905-7. PubMed ID: 21788466
    [TBL] [Abstract][Full Text] [Related]  

  • 4. FDA treads carefully with PrEP.
    Holmes D
    Lancet Infect Dis; 2012 Jul; 12(7):515-6. PubMed ID: 22930826
    [No Abstract]   [Full Text] [Related]  

  • 5. Preexposure chemoprophylaxis for HIV prevention.
    Pimpinella G; Malgarini RB
    N Engl J Med; 2011 Apr; 364(14):1373; author reply 1374-5. PubMed ID: 21470024
    [No Abstract]   [Full Text] [Related]  

  • 6. The British HIV Association/British Association for Sexual Health and HIV Position Statement on pre-exposure prophylaxis in the UK.
    McCormack S; Fidler S; Fisher M; ;
    Int J STD AIDS; 2012 Jan; 23(1):1-4. PubMed ID: 22362679
    [No Abstract]   [Full Text] [Related]  

  • 7. Preexposure chemoprophylaxis for HIV prevention.
    Underhill K
    N Engl J Med; 2011 Apr; 364(14):1374; author reply 1374-5. PubMed ID: 21470023
    [No Abstract]   [Full Text] [Related]  

  • 8. Preexposure chemoprophylaxis for HIV prevention.
    Pittrof R; Sauer U; French P
    N Engl J Med; 2011 Apr; 364(14):1374; author reply 1374-5. PubMed ID: 21470022
    [No Abstract]   [Full Text] [Related]  

  • 9. Preexposure chemoprophylaxis for HIV prevention.
    Lee DH; Vielemeyer O
    N Engl J Med; 2011 Apr; 364(14):1372-3; author reply 1374-5. PubMed ID: 21470026
    [No Abstract]   [Full Text] [Related]  

  • 10. Integrating HIV prevention into practice.
    Mathers BM; Cooper DA
    JAMA; 2014 Jul 23-30; 312(4):349-50. PubMed ID: 25038352
    [No Abstract]   [Full Text] [Related]  

  • 11. Preexposure chemoprophylaxis for HIV prevention.
    Sellier PO; Lafuente-Lafuente C; Roques P
    N Engl J Med; 2011 Apr; 364(14):1373; author reply 1374-5. PubMed ID: 21470025
    [No Abstract]   [Full Text] [Related]  

  • 12. Ethics and pre-exposure prophylaxis for HIV infection.
    Sugarman J; Mayer KH
    J Acquir Immune Defic Syndr; 2013 Jul; 63 Suppl 2(0 2):S135-9. PubMed ID: 23764625
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Systemic preexposure prophylaxis for HIV: translating clinical data to clinical practice.
    Li J; Dufrene SL; Okulicz JF
    Ann Pharmacother; 2014 Apr; 48(4):507-18. PubMed ID: 24473492
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Emtricitabine/tenofovir disoproxil fumarate: a review of its use in HIV-1 pre-exposure prophylaxis.
    Plosker GL
    Drugs; 2013 Mar; 73(3):279-91. PubMed ID: 23444256
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Update to Interim Guidance for Preexposure Prophylaxis (PrEP) for the Prevention of HIV Infection: PrEP for injecting drug users.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2013 Jun; 62(23):463-5. PubMed ID: 23760186
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Study design considerations for evaluating efficacy of systemic preexposure prophylaxis interventions.
    Donnell D; Hughes JP; Wang L; Chen YQ; Fleming TR
    J Acquir Immune Defic Syndr; 2013 Jul; 63 Suppl 2(0 2):S130-4. PubMed ID: 23764624
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oral preexposure anti-HIV prophylaxis for high-risk U.S. populations: current considerations in light of new findings.
    Myers GM; Mayer KH
    AIDS Patient Care STDS; 2011 Feb; 25(2):63-71. PubMed ID: 21284497
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Emtricitabine-tenofovir concentrations and pre-exposure prophylaxis efficacy in men who have sex with men.
    Anderson PL; Glidden DV; Liu A; Buchbinder S; Lama JR; Guanira JV; McMahan V; Bushman LR; Casapía M; Montoya-Herrera O; Veloso VG; Mayer KH; Chariyalertsak S; Schechter M; Bekker LG; Kallás EG; Grant RM;
    Sci Transl Med; 2012 Sep; 4(151):151ra125. PubMed ID: 22972843
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recent HIV-1 infection: to treat or not to treat, that is the question.
    Tossonian H; Conway B
    J Infect Dis; 2012 Jan; 205(1):10-2. PubMed ID: 22180623
    [No Abstract]   [Full Text] [Related]  

  • 20. Switching STRATEGIES in HIV treatment.
    Schrijvers R; Debyser Z
    Lancet Infect Dis; 2014 Jul; 14(7):537-40. PubMed ID: 24908549
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 18.